Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly-beta-1,6-N-acetyl-D-glucosamine N-deacetylase (PgaB) is a periplasmic bacterial enzyme classified in the carbohydrate esterase family 4 (CE4)[1][3]. It participates in biofilm formation by catalyzing the partial de-N-acetylation of the exopolysaccharide PNAG, a modification required for strong intercellular adhesion and biofilm integrity in Escherichia coli and other Gram-negative bacteria[1][3][8]. Structurally, PgaB contains an N-terminal de-N-acetylase domain and a C-terminal domain involved in polymer binding and/or export, sometimes facilitated by interaction with other biofilm machinery proteins, such as PgaA[2]. The enzyme’s specificity and efficiency are governed by a unique active site and metal (Ni2+, Fe3+) coordination, and its function impacts bacterial survival and pathogenicity[1][2][3][8]. Targeting PgaB or its activity is of therapeutic interest in the context of anti-biofilm strategies for combating chronic bacterial infections[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly-beta-1,6-N-acetyl-D-glucosamine N-deacetylase (PgaB).